1. Home
  2. MTG vs DFTX Comparison

MTG vs DFTX Comparison

Compare MTG & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MGIC Investment Corporation

MTG

MGIC Investment Corporation

N/A

Current Price

$28.94

Market Cap

5.6B

Sector

Finance

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$32.68

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MTG
DFTX
Founded
1957
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.9B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
MTG
DFTX
Price
$28.94
$32.68
Analyst Decision
Hold
Strong Buy
Analyst Count
7
19
Target Price
$30.83
★ $72.56
AVG Volume (30 Days)
★ 2.2M
1.9M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
★ 2.39%
N/A
EPS Growth
★ 8.65
N/A
EPS
★ 1.62
N/A
Revenue
★ $1,213,636,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.04
N/A
P/E Ratio
$17.53
★ N/A
Revenue Growth
★ 0.49
N/A
52 Week Low
$24.69
$14.62
52 Week High
$31.89
$49.70

Technical Indicators

Market Signals
Indicator
MTG
DFTX
Relative Strength Index (RSI) 55.27 38.72
Support Level $25.59 $32.43
Resistance Level $29.37 $38.04
Average True Range (ATR) 0.62 1.85
MACD 0.20 0.20
Stochastic Oscillator 86.84 19.79

Price Performance

Historical Comparison
MTG
DFTX

About MTG MGIC Investment Corporation

MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: